Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for major depressive disorder in patients with advanced cancer receiving palliative care
ACTRN12610001011077Phase 2Recruiting
- Sponsor
- University of Otago
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in major depressive disorder (MDD) (5 arms), sponsored by University of Otago. Primary endpoint: Montgomery-Asberg Depression Rating Scale (MADRS). Started Mar 2011; status: recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12610001011077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610001011077.